ASIT biotech: Additional Information: Declaration of Dissociation of a Member of the Board of Directors at the General Assembly

BRUSSELS--()--Regulatory News:

ASIT biotech (BSE:ASIT) (Paris:ASIT) (ASIT - BE0974289218), Announces that the Press Release of Thursday 14th November at 23:00 entitled ‘Declaration of dissociation of a member of the Board of Directors at the General Assembly’ was not containing the minutes of the General Assembly as an attachment in some communication channels and was therefore not forming the full version of the Press Release. This has been corrected and the full version is available on the ASIT biotech’s website here.

About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech’s product pipeline contains three novel ASIT+™ product candidates targeting respiratory allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+™ - in ongoing phase III - and house dust mite: hdm-ASIT+™), and food allergies (peanut allergy: pnt-ASIT+™) that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

Further information can be found at www.asitbiotech.com.

Follow us on LinkedIn

Legal notice

This announcement is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company’s shares in any jurisdiction. This announcement does not constitute a prospectus. Any purchase of, subscription for or application for, Shares to be issued in connection with the intended offering should only be made on the basis of information contained in the prospectus and any supplements thereto, as the case may be.

Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guaranteeing future results. These forward-looking statements speak only as of the date of publication of this document. The Company expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

Contacts

Company
Michel Baijot, CEO
ASIT biotech
Tel.: +32 2 264 03 90
investors@asitbiotech.com

Investor Relations
LifeSci Advisors LLC
Hans Herklots
Tel.: +41 79 598 7149
hherklots@lifesciadvisors.com

Media Relations
Sophie Baumont
Tel.: +33 627 74 74 49
sophie@lifesciadvisors.com

Contacts

Company
Michel Baijot, CEO
ASIT biotech
Tel.: +32 2 264 03 90
investors@asitbiotech.com

Investor Relations
LifeSci Advisors LLC
Hans Herklots
Tel.: +41 79 598 7149
hherklots@lifesciadvisors.com

Media Relations
Sophie Baumont
Tel.: +33 627 74 74 49
sophie@lifesciadvisors.com